Look at the recent hot search, “giving birth to a baby” is definitely one of the hottest topics of the two sessions this year.
The concept of assisted reproduction also rose strongly in today’s session. As of press time, Tianjin Tianyao Pharmaceutical Co.Ltd(600488) , Changjiangrunfa Health Industry Co.Ltd(002435) , Dajia Weikang, Xilong Scientific Co.Ltd(002584) , Changchun High And New Technology Industries (Group) Inc(000661) , etc. have risen by more than 6%.
Among them, Changjiangrunfa Health Industry Co.Ltd(002435) has been trading for five consecutive trading days.
On the morning of March 10, some companies also disclosed on the investor interaction platform that they are actively entering the field of assisted reproduction.
Beijing incorporated assisted reproduction into medical insurance
many provinces said: “arrangement!”
A few days ago, Sichuan Provincial Health Commission responded to netizens’ message of “subsidizing assisted reproduction”, saying that it plans to learn from the practices of individual provinces and cities and actively strive to include common assisted reproductive technology projects into the scope of medical insurance reimbursement in conjunction with relevant departments.
In response to the suggestion of Shandong netizens on “bringing families that must rely on assisted reproductive technology to have children into medical insurance”, the relevant departments in Shandong also replied on March 9 that in the next step, Shandong will earnestly implement the national medical insurance catalogue management policy according to the requirements of the national unified deployment, based on the positioning of “basic protection”, and on the basis of scientific calculation and full demonstration, Gradually include the diagnosis and treatment projects with mature technology, safety and reliability and controllable cost that can be borne by medical insurance into the scope of medical insurance payment according to procedures, and strive to improve the level of patient protection.
On February 21, the Beijing Medical Insurance Bureau officially announced that 16 assisted reproductive technology projects were included in the category a reimbursement scope of medical insurance, which was officially implemented on March 26.
On the day after Beijing released the new medical insurance policy, Shanghai Medical Insurance Bureau launched a research meeting to study the possibility of assisted childbirth into medical insurance. Guangdong Province has also introduced measures to reduce the threshold for receiving maternity insurance benefits. The “provisions on maternity insurance for employees in Guangdong Province” stipulates that as long as the unit pays the social security in January, it can enjoy maternity insurance benefits next month.
The continuous decline in the number of women of childbearing age, the change in the reproductive concept of young people, high life pressure, high house prices, high childbearing and parenting costs, and the impact of epidemic factors have made some people do not want to have children or delay having children.
In real life, some couples of childbearing age may be suffering from infertility. Giving birth to a baby is expensive, which is a big problem in front of it.
The well-known assisted reproductive technology is generally IVF and artificial insemination, which is also the most commonly used assisted reproductive technology with high success rate. The reporter learned that in the assisted reproductive technology center, the biggest demand is the “test tube baby” technology. This technology includes examination and treatment. The single cost is about 38000 yuan to 50000 yuan. More than half of the patients need two or more treatments to succeed.
NPC and CPPCC deputies heated discussion on the issue of “giving birth to children
In 2021, China’s birth rate was only 7.52 ‰, a record low since the founding of China. During the two sessions this year, many representatives and members made suggestions for the inclusion of assisted reproduction in medical insurance, so as to promote the better implementation of the national fertility policy.
Liang Yijian, deputy to the National People’s Congress and director of orthopedics department of Chengdu Third People’s Hospital, submitted the proposal on the support of the national medical insurance bureau to include the medical expenses of artificial assisted reproductive technology (IVF) into medical insurance reimbursement to the conference. In Liang Yijian’s view, China is facing the problem of declining fertility rate of women of childbearing age and increasing infertility rate of couples of childbearing age. “All kinds of assisted reproductive technologies have developed rapidly and the technical level has gradually improved, bringing hope to infertile couples.”
In his speech at the group meeting, Liu Yingcai, deputy to the National People’s Congress, suggested that the cost of analgesic delivery and assisted reproduction should be included in the medical insurance project to promote the better implementation of the national fertility policy.
Zhou Songbo, deputy to the National People’s Congress and President of Fanyang hospital in Zhuozhou, Hebei Province, said that we should encourage the research and development of emerging assisted reproductive technologies and incorporate mature and safe assisted reproductive technologies into medical insurance.
The inclusion of IVF in medical insurance is undoubtedly a great good news for infertile people, which fundamentally reduces their cost burden and gives more infertile people who have been waiting because of economic pressure the opportunity to use assisted reproductive technology.
In addition, many young people now work hard in their twenties and thirties to choose late marriage and late childbirth, and there will be an increasing demand for assisted reproduction. The inclusion of IVF in medical insurance will allow more older people to try to have children.
industry is a blue ocean
investors need to be rational
From the perspective of industrial chain, the assisted reproductive industry has formed an industrial chain with “medical device / medicine supply, Internet assisted reproductive medical platform terminal service” as the system.
The upstream of assisted reproduction industry is the supplier of drugs, devices and testing reagents. Assisted reproductive drugs include lowering regulation, ovulation induction, ovulation induction and corpus luteum support. Multinational pharmaceutical companies Merck, shiranor and MSD have obvious competitive advantages. With the improvement of China’s R & D and innovation level and the improvement of generic drug consistency evaluation, Livzon Pharmaceutical Group Inc(000513) , Zhejiang Xianju Pharmaceutical Co.Ltd(002332) and other Chinese pharmaceutical enterprises are accelerating their penetration into the high-end market; In the field of assisted reproductive device production, foreign manufacturers almost monopolize the device market.
The middle reaches of the industrial chain are assisted reproductive service institutions. Relying on the advantages of Internet channels, institutions providing assisted reproductive peripheral services launch online consultation app, realize accurate customer acquisition offline through medical service entities, and then drain to the downstream assisted reproductive medical service institutions. Online service enterprises such as haoyubang, Beibei and Dr. Edin are all participants.
The downstream of the industry is assisted reproductive medical service institutions. The market concentration in this field is low, the competition pattern is highly dispersed, and the advantages of public medical institutions are more obvious.
Some investment bankers told reporters that Beijing will include assisted reproduction in medical insurance, and other provinces and cities will actively follow up. The penetration rate of assisted reproduction industry is expected to increase significantly. From the supply side, public hospitals have limited capacity, and subsequent private hospitals are expected to usher in a window period by attracting customers through value-added services. However, it may be difficult to see a surge in demand in the short term. I hope investors can rationally view the “new blue ocean” opportunity.
